[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志, 2018, 26: 195-203.
[2] Carr RM, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res, 2016, 340: 187-192.
[3] Itabe H, Yamaguchi T, Nimura S, et al. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis, 2017, 16: 83.
[4] Wolins NE, Quaynor BK, Skinner JR, et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes, 2006, 55: 3418-3428.
[5] Kimmel AR, Sztalryd C. Perilipin 5, a lipid droplet protein adapted to mitochondrial energy utilization. Curr Opin Lipidol, 2014, 25: 110-117.
[6] Dalen KT, Dahl T, Holter E, et al. LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. Biochim Biophys Acta, 2007, 1771: 210-227.
[7] Hashani M, Witzel HR, Pawella LM, et al. Widespread expression of perilipin 5 in normal human tissues and in diseases is restricted to distinct lipid droplet subpopulations. Cell Tissue Res, 2018, 374: 121-136.
[8] Wolins NE, Brasaemle DL, Bickel PE. A proposed model of fat packaging by exchangeable lipid droplet proteins. FEBS Lett, 2006, 580: 5484-5491.
[9] Benador IY, Veliova M, Mahdaviani K, et al. Mitochondria bound to lipid droplets have unique bioenergetics, composition, and dynamics that support lipid droplet expansion. Cell Metab, 2018, 27: 869-885.e6.
[10] Trevino MB, Mazur-Hart D, Machida Y, et al. Liver perilipin 5 expression worsens hepatosteatosis but not insulin resistance in high fat-fed mice. Mol Endocrinol, 2015, 29: 1414-1425.
[11] Drevinge C, Dalen KT, Mannila MN, et al. Perilipin 5 is protective in the ischemic heart. Int J Cardiol, 2016, 219: 446-454.
[12] Gemmink A, Daemen S, Kuijpers HJH, et al. Super-resolution microscopy localizes perilipin 5 at lipid droplet-mitochondria interaction sites and at lipid droplets juxtaposing to perilipin 2. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863: 1423-1432.
[13] Wang H, Sreenivasan U, Hu H, et al. Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res, 2011, 52: 2159-2168.
[14] Pollak NM, Jaeger D, Kolleritsch S, et al. The interplay of protein kinase A and perilipin 5 regulates cardiac lipolysis. J Biol Chem, 2015, 290: 1295-1306.
[15] Keenan SN, De Nardo W, Lou J, et al. Perilipin 5 S155 phosphorylation by PKA is required for the control of hepatic lipid metabolism and glycemic control. J Lipid Res, 2021, 62: 100016.
[16] Pawella LM, Hashani M, Eiteneuer E, et al. Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol, 2014, 60: 633-642.
[17] Ma SY, Sun KS, Zhang M, et al. Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD. Liver Int, 2020, 40: 2427-2438.
[18] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation, 2019, 103: e1-e13.
[19] Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab, 2015, 21: 739-746.
[20] Keenan SN, Meex RC, Lo JCY, et al. Perilipin 5 deletion in hepatocytes remodels lipid metabolism and causes hepatic insulin resistance in mice. Diabetes, 2019, 68: 543-555.
[21] Shum M, Ngo J, Shirihai OS, et al. Mitochondrial oxidative function in NAFLD: Friend or foe? Mol Metab, 2021, 50: 101134.
[22] Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol, 2018, 68: 280-295.
[23] Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, et al. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci, 2018, 19: 2034.
[24] Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology, 2020, 158: 1984-1998. e3.
[25] Li H, Song Y, Zhang LJ, et al. LSDP5 enhances triglyceride storage in hepatocytes by influencing lipolysis and fatty acid beta-oxidation of lipid droplets. PLoS One, 2012, 7: e36712.
[26] Wang C, Zhao Y, Gao X, et al. Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. Hepatology, 2015, 61: 870-882.
[27] Varghese M, Kimler VA, Ghazi FR, et al. Adipocyte lipolysis affects perilipin 5 and cristae organization at the cardiac lipid droplet-mitochondrial interface. Sci Rep, 2019, 9: 4734.
[28] Schuldiner M, Bohnert M. A different kind of love-lipid droplet contact sites. Biochim Biophys Acta Mol Cell Biol Lipids, 2017, 1862: 1188-1196.
[29] Asimakopoulou A, Engel KM, Gassler N, et al. Deletion of perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation. Cells, 2020, 9: 1346.
[30] Lin J, Chen A. Perilipin 5 restores the formation of lipid droplets in activated hepatic stellate cells and inhibits their activation. Lab Invest, 2016, 96: 791-806.
[31] Tan Y, Jin Y, Wang Q, et al. Perilipin 5 protects against cellular oxidative stress by enhancing mitochondrial function in HepG2 cells. Cells, 2019, 8: 1241.
[32] Zhu Y, Ren C, Zhang M, et al. Perilipin 5 reduces oxidative damage associated with lipotoxicity by activating the pi3k/erk-mediated nrf2-are signaling pathway in ins-1 pancreatic beta-cells. Front Endocrinol (Lausanne), 2020, 11: 166.
[33] Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci (Lond), 2017, 131: 2701-2704.
[34] Lee J, Park JS, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res, 2019, 42: 935-946.
[35] Mason RR, Mokhtar R, Matzaris M, et al. PLIN5 deletion remodels intracellular lipid composition and causes insulin resistance in muscle. Mol Metab, 2014, 3: 652-663.
[36] Gemmink A, Bosma M, Kuijpers HJ, et al. Decoration of intramyocellular lipid droplets with PLIN5 modulates fasting-induced insulin resistance and lipotoxicity in humans. Diabetologia, 2016, 59: 1040-1048.
[37] Gemmink A, Daemen S, Brouwers B, et al. Dissociation of intramyocellular lipid storage and insulin resistance in trained athletes and type 2 diabetes patients; involvement of perilipin 5? J Physiol, 2018, 596: 857-868.
[38] Trivedi P, Wang S, Friedman SL. The power of plasticity-metabolic regulation of hepatic stellate cells. Cell Metab, 2021, 33: 242-257.
[39] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol, 2021, 18: 151-166.
[40] Lin J, Zheng S, Attie AD, et al. Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. J Lipid Res, 2018, 59: 416-428.
[41] Cierpka R, Weiskirchen R, Asimakopoulos A. Perilipin 5 ameliorates hepatic stellate cell activation via smad2/3 and snail signaling pathways and suppresses STAT3 activation. Cells, 2021, 10: 2184. |
